Type here...

Home
About
Editor’s Corner
Contribute
Contact Us

Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
Solutions & Pricing
Partner

Instagram

Twitter

Thursday, March 19, 2026

28.3 C

Bengaluru

Home
About
Editor’s Corner
Contribute
Contact Us

My account

Get into your account.

type here...

Facebook

Twitter

Youtube

Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

Violence Against Medics – Lessons to Draw from Private Hospitals

One interesting fact: most medical colleges and linked public hospitals in major cities were designed in the British era, with an open ward design. A medical administrator, tongue-in-cheek, put it succinctly: “When these hospitals were designed, nobody would have imagined that doctors will face violence”. Time for design thinking in public healthcare delivery!

Indian Pharma Market Through a Game Theory Lens

A Salil Kallianpur Blog Explosive value growth, limited volume growth –...

India’s Patent Revocations: Strengthening Access and Challenging Evergreening

The Indian Patent Office’s recent decision to revoke Novartis’...

IMS Health Market Reflection Report for June 2016

Every month, MedicinMan in partnership with IMS Health, brings our readers the latest industry numbers related to sales and revenues of different companies, brands and therapy areas in the Indian Pharmaceutical Market.

DiME (Digi MarketEr):-TiME to SHiNE

The new sparkling DIME (Digi MarketEr) are the ones who embrace digital transformation with open arms and voraciously feed on data analytics to satisfy their performance outcomes with an informed business decision. The benefit of being DIME is that it propels data management out of the hands of individual stakeholders, and puts data sets with insights on to center glass table (Transparent workplace) for informed decision making.

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

Excellence or Mediocrity—What Are You Building?

Excellence is a choice. So is Mediocrity Excellence is a...

Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution

In the blistering Sonoran Desert, where temperatures regularly exceed...

The Quiet Crisis in the Indian Pharma Field Force

A MedicinMan Editorial based on the Poll framed by...

The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience

A recent industry spotlight by Venkat Mutavi notes a...

IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars

India's pharmaceutical market charged into 2026 with strong momentum,...

Marketing

Excellence or Mediocrity—What Are You Building?

Excellence is a choice. So is Mediocrity Excellence is a...

Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution

In the blistering Sonoran Desert, where temperatures regularly exceed...

The Quiet Crisis in the Indian Pharma Field Force

A MedicinMan Editorial based on the Poll framed by...

The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience

A recent industry spotlight by Venkat Mutavi notes a...

IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars

India's pharmaceutical market charged into 2026 with strong momentum,...

Policies/Sales

Excellence or Mediocrity—What Are You Building?

Excellence is a choice. So is Mediocrity Excellence is a...

Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution

In the blistering Sonoran Desert, where temperatures regularly exceed...

The Quiet Crisis in the Indian Pharma Field Force

A MedicinMan Editorial based on the Poll framed by...

The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience

A recent industry spotlight by Venkat Mutavi notes a...

IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars

India's pharmaceutical market charged into 2026 with strong momentum,...

Strategy

Excellence or Mediocrity—What Are You Building?

Excellence is a choice. So is Mediocrity Excellence is a...

Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution

In the blistering Sonoran Desert, where temperatures regularly exceed...

The Quiet Crisis in the Indian Pharma Field Force

A MedicinMan Editorial based on the Poll framed by...

The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience

A recent industry spotlight by Venkat Mutavi notes a...

IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars

India's pharmaceutical market charged into 2026 with strong momentum,...

Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

DigiStorm 2018: Intent, Content, Strategy and Skills

The pharma industry in India is entering a very interesting variant of the post-digital marketing era. The term “post-digital marketing” is used to depict a state where the lines between physical and digital blur considerably for a customer. However, in the context of pharma, this means a state where the industry has stopped questioning the need for digital and has begun to implement very interesting digital marketing initiatives.

The Future in Your Palm+Chemistry – Palmistry

The future in your palm - a non-contact wearable...

Medical Rep to Chairman & Managing Director – Sunil Attavar’s Success Story

Q 1. Tell us about your journey as a pharma entrepreneur and what made you venture into pharma and stay on in pharma? My journey started with two good decisions, one- to be a Medical Representative (MR) in Mumbai, which built a strong foundation and the other, to join Helios, a new pharma company, which was like a baptism of fire. Together, they molded me well. I was promoted as a Front Line Manager (FLM) within a year. And after spending four excellent years in Helios, I joined Group Pharma as Product Manager (PM) and ever since, it’s been an exciting learning experience. I was exposed to Pharma very early in life as my dad was in J L Morison, as part of the promoter-team of Warren Pharma. At home, I was the designated telephone operator and order processing clerk. Those were the days of trunk-calls - calling managers and distributors to note down orders. Hence, I was exposed to the excitement of targets, achievements, deficits and campaigns very early in my life. The idea of ‘work-life balance’ was not in vogue. One would look to their parents who worked long hours with pride making it something you wanted to emulate. Things have changed a lot but I would not trade the decision I made, to get into and stay in Pharma.